TABLE 10.

Secondary parameters describing the population pharmacokinetics of artemether and dihydroartemisinin^a

Drug and secondary parameter	Median value (range) for group
	3 days		5 days
	Nonpregnant	Pregnant	Nonpregnant	Pregnant
Artemether
Tmax (h)	0.93 (0.71–2.41)	0.890 (0.540–1.83)	0.880 (0.710–1.71)	0.880 (0.530–1.63)
Cmax (ng/ml)	67.6 (30.1–136)	42.5 (25.3–86.8)	63.3 (35.1–137)	42.5 (29.0–67.7)
AUC0–60 (h · ng/ml)	1,710 (617–3,870)	948 (511–2,530)	2,120 (1,210–4,110)	1,610 (929–2,370)
Half-life (h)	2.67 (2.09–4.71)	2.53 (1.73–4.05)	2.39 (1.59–2.98)	2.45 (1.73–3.78)
Dihydroartemisinin
Tmax (h)	1.38 (1.06–2.71)	1.35 (1.10–2.16)	1.35 (1.15–2.23)	1.35 (1.05–1.96)
Cmax (ng/ml)	57.3 (24.7–114)	42.5 (25.3–86.8)	59.8 (28.1–137)	38.0 (21.8–65.6)
AUC0–60 (h · ng/ml)	1,600 (558–2,700)	948 (511–2,530)	2,350 (1,260–4,740)	1,500 (932–2,380)
Half-life (h)	0.210 (0.140–0.300)	0.210 (0.130–0.300)	0.220 (0.180–0.290)	0.210 (0.170–0.270)

^aT_max is the time to reach the maximum concentration (C_max). AUC_0–60 is the total exposure from the first dose to day 60.